Avoro Capital Advisors LLC 13D and 13G filings for Iovance Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 09:31 am Sale | 2022-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA | Avoro Capital Advisors LLC | 7,020,000 4.400% | -1,655,000 (-19.08%) | Filing |
| 2022-02-11 10:04 am Purchase | 2021-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA | Avoro Capital Advisors LLC | 8,675,000 5.500% | 1,175,000 (+15.67%) | Filing |
| 2021-02-12 08:03 am Sale | 2020-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA | Avoro Capital Advisors LLC | 7,500,000 5.100% | -1,326,039 (-15.02%) | Filing |
| 2020-02-24 4:17 pm Sale | 2019-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA | Avoro Capital Advisors LLC | 8,826,039 7.000% | -738,961 (-7.73%) | Filing |
| 2020-02-14 10:04 am Sale | 2019-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA | Avoro Capital Advisors LLC | 9,565,000 7.600% | -1,435,000 (-13.05%) | Filing |